NCT01977677View on ClinicalTrials.gov

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

September 30, 2018

Conditions
Adult EpendymoblastomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult MedulloblastomaAdult Mixed GliomaAdult Oligodendroglial TumorsAdult PineoblastomaAdult Supratentorial Primitive Neuroectodermal Tumor (PNET)
Interventions
RADIATION

radiation therapy

Undergo radiation therapy

DRUG

temozolomide

Given PO

DRUG

plerixafor

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Lawrence Recht

OTHER

NCT01977677 - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | Biotech Hunter | Biotech Hunter